Search This Blog

Wednesday, July 4, 2018

Zeiss Ups Revenue Outlook


ZEISS, a technology enterprise operating in the fields of optics and optoelectronics, issued the following news release:
Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of approximately EUR 926 million in the first nine months of fiscal year 2017/18, based on preliminary data. This corresponds to revenue growth of approximately 7% vs. the previous year’s value of EUR 864.7 million. After adjustment for currency effects1), growth amounted to around 12 %.
For the fiscal year 2017/18, Carl Zeiss Meditec now expects revenue of between EUR 1,250 to EUR 1,300 million (previously: EUR 1,230 to EUR 1,280 million).
At this point in time, further financial information is not yet available. The 9-months quarterly statement for fiscal year 2017/18 will be published on August 10, 2018.

Dubai regulator probes private equity firm Abraaj over alleged mismanagement

gulator is investigating allegations of mismanagement at private equity firm Abraaj, which is on the verge of financial collapse after a scandal over its use of investor money, two sources familiar with the matter said.

The Dubai Financial Services Authority (DFSA) has interviewed the firm’s founder, Arif Naqvi, and other senior executives in the past few months as part of the probe, the sources said.
The DFSA declined to comment. Abraaj said in a statement discussions between it and the regulator were “ongoing.”
“The DFSA is kept apprised of developments in the overall Abraaj Group and has our full co-operation on all relevant matters,” Abraaj said.
“While we do not comment on confidential discussions with our regulators, we are highly focused on strengthening our corporate governance and internal controls.”
A third source said Abraaj co-chief executives Omar Lodhi and Selcuk Yorgancioglu were among those questioned by the regulator.
There was no immediate comment from Naqvi or his legal representative. There was also no immediate comment from Lodhi. Yorgancioglu referred a Reuters request for comment to Abraaj.
The investigation heaps more pressure on Abraaj which is trying to sell its investment management business to Colony Capital following a dispute with some of its investors over the use of money in a $1 billion healthcare fund.
This erupted late last year, when investors including the Bill & Melinda Gates Foundation and the International Finance Corp made allegations that Abraaj mishandled their money in the healthcare fund. Abraaj has denied misusing the funds.
The allegations triggered a solvency crisis at the fund, the biggest buyout fund in Middle East and North Africa.
After halting fund raising activities and shaking up management, Abraaj last month filed for provisional liquidation in the Cayman Islands as it seeks an agreement with creditors and is selling parts of its businesses.
Summary findings of a review by Deloitte, appointed by Abraaj to audit its operations, said that a cash shortage at the firm led it to dip into investor funds.
Deloitte said on June 4 there was no evidence of embezzlement or misappropriation, but highlighted a lack of “adequate governance” and “overall weakness” at Abraaj.
In a statement on June 21, the DFSA had said it would be “discussing various matters with the Joint Provisional Liquidators of Abraaj Holdings and Abraaj Investment Management Limited and would continue to work toward safeguarding the interests of investors.”
DFSA has the power to fine or ban individuals from working in financial services within the Dubai International Financial Centre (DIFC) and has in the past imposed penalties for rule breaches. For companies, that can lead to a fine or even a suspension from operating in the center.
Abraaj has a regulated entity, Abraaj Capital, in the DIFC.
In its statement, Abraaj said it was premature to speculate on actions that the regulator may or may not consider.
“We believe these are decisions best communicated by the regulator in the fullness of time and early speculation is unhelpful to the process,” the statement said.
The affair has raised concerns in the finance industry that Dubai’s reputation as a major financial center could suffer.
Dubai’s main stock market index <.DFMGI> is down 15 percent so far this year, making it one of the worst performing in the region. The market has been partly affected by the Abraaj situation as well as weakness in the property sector.
“It is easy to fault regulators and auditors in retrospect,” said Richard Segal, senior analyst at Manulife Asset Management, adding that it was not easy to detect mismanagement.
“One might also argue that the investor oversight that brought these issues into the open might prove to be timely.”

A Cardio Routine That Prevents Injuries


This cardio burner will also help prevent injury, says Chris Heuisler, global runWestin concierge for Westin Hotels and Resorts. Do 8 reps per move and repeat the circuit for 20 minutes.
1Alternating Crab Reach
cardio moves for runners
MATT RAINEY
Sit with palms and feet flat, fingertips pointed back. Drive hips up and reach right arm over head to left side. Return to start; repeat on other side for 1 rep.
2Plank With Knee-Drive
cardio moves for runners
MATT RAINEY
Start in a high plank. Keeping abs engaged tight, explosively drive left knee to right elbow. Return to start; quickly repeat on other side for 1 rep.
3Side Lunge and Balance
cardio moves for runners
MATT RAINEY
From standing, step right foot out into a lunge, keeping left leg straight. Drive off right foot to return to start, hovering right foot next to left; hold 1 beat. Do reps; switch legs.
4Lateral Pushup
cardio moves for runners
MATT RAINEY
Start in high plank. Move left hand and foot to the left, then bring right hand and foot to meet. Do a pushup. Move right hand and foot to right; follow with left hand and foot. Do a pushup. That’s 1 rep.
5Squat-Cross-Punch
cardio moves for runners
MATT RAINEY
Squat low with back flat, chest raised. As you rise up, rotate hips to the left and punch with right fist. Rotate back to center; repeat on other side for 1 rep.

6Skaters
cardio moves for runnerscardio moves for runners
MATT RAINEY
From standing, push off right foot to jump a couple feet to the left. Land on left foot and let right foot swing behind you, speed-skater style. Quickly repeat on other side for 1 rep.

Inhaler Device Errors Common Among Health Care Providers


Healthcare providers (HCPs) lack knowledge on appropriate inhaler technique, according to a systematic review published in the May/June issue of the Journal of Allergy and Clinical Immunology: In Practice. The lack of knowledge may lead to ineffective therapy when HCPs teach patients how to use pressurized metered-dose inhalers or dry powder inhalers for the management of respiratory conditions.
“These results highlight the urgent need to design efficient strategies to improve the training of [HCPs] in the appropriate use of inhalers,” write lead author Vicente Plaza, MD, PhD, from the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, and colleagues.
The authors reviewed studies that assessed inhaler technique among HCPs and were published between January 1975 and December 2014. They identified 404 studies, of which 55 met the inclusion criteria and were included in the analysis. These included data on 6034 HCPs across a variety of disciplines, with a total of 9993 tests of the inhaler technique performed.
Overall, inhaler technique was considered correct in only 15.5% of cases (95% confidence interval [CI], 12% – 19.3%). Moreover, the proportion declined significantly from the early study period (defined as 1975 to 1995) to the later part (1996 to 2014), going from 20.5% (95% CI, 14.9% – 26.8%) to 10.8% (95% CI, 7.3% -14.8%).
Further, the authors found that two of the most common errors (lack of coordination and forceful rapid inhalation) were considered critical errors based on previous study findings because of “their association with uncontrolled asthma and/or increased rates of exacerbations.”
When compared with a previous study assessing inhaler technique among 54,354 patients, Plaza and colleagues note “HCPs correctly performed [inhaler technique] only half as often as patients did (15.5% vs 31%, respectively)” and that the mean inhaler technique error rates across various devices “were notably higher among HCPs and similar to the rates that would be expected from a treatment-naive subject using an inhaler for the first time.”
The study authors acknowledge that the heterogeneity of the study groups, as well as the inability to appropriately assess the risk of bias across all studies, was a potential limitation.
“Patient training and education in the use of inhalers is an essential part of the tasks of HCPs involved in the care of chronic respiratory patients, including physicians, respiratory therapists, nurses, and pharmacists,” Plaza and colleagues write.
“It is likely that specific and repeated — a key element — educational programs addressed to HCPs according to their needs could improve [inhaler technique] among those professionals, thus leading to greater success in instructing patients in proper inhaler use,” they conclude.
No funding was received for this study. The authors have disclosed no relevant financial relationships.
J Allergy Clin Immunol Pract. 2018;6:987-995. Abstract

Vaccinations are a significant part of your pet’s healthcare


Your veterinarian sends you a reminder to book an appointment for your pet’s vaccinations. This may seem unimportant, but actually it is a very significant part of your pet’s healthcare. Vaccines protect dogs and cats from infectious agents that can cause serious illness or may be fatal. As in humans, vaccines have had a major impact in decreasing infectious diseases and are very safe. Nowadays we don’t see many of these diseases. This is largely due to ongoing and regular pet vaccination. The benefits of vaccinations far outweigh the low risk of adverse reactions. By continuing to vaccinate our pets, we can ensure the health of our companions.
Major Vaccine Preventable Diseases
Rabies is one of the most well-known diseases as it is fatal in animals and humans. Rabies is caused by a virus that infects the nervous system and can lead to increased salivation, aggression and death. Rabies virus is transmitted through animal bites, and is found in wildlife such as bats, raccoons, foxes, and skunks.
Canine distemper virus attacks the respiratory, gastrointestinal, and nervous systems. Distemper can be fatal. Dogs that survive may have lifelong complications. Wildlife such as coyotes, raccoons, skunks, and foxes may also be infected.
Canine parvovirus can cause severe vomiting and diarrhea (often bloody), and can lead to sudden death in unvaccinated puppies. It is one of the most lethal infections of dogs. Parvovirus is transmitted through contact with an infected animal stool.
Canine adenovirus causes coughing, sneezing and infectious canine hepatitis (ICH). ICH clinical signs can range from mild fever to death; it is rare because of effective vaccination programs for dogs. Current vaccines for canine adenovirus protect against both diseases.
Feline parvovirus, also known as panleukopenia, is a highly fatal virus particularly in kittens and causes diarrhea and decreases in white blood cells. The virus is very contagious and can be spread directly from infected feces and fluids.
Feline herpesvirus causes a disease of the upper respiratory tract, also known as viral rhinotracheitis. Kittens and cats may have runny noses and eye infections leading to pneumonia, and cats can be carriers for life. The disease can be fatal, particularly in combination with other viruses or bacteria, and is spread from infected oral, nasal, and ocular fluids.
Feline calicivirus causes clinical signs similar to feline rhinotracheitis; cats may present with mouth sores or lameness.

Fertility problems, reproductive tech tied to slightly more birth defects


Women who struggle to get pregnant or use reproductive technologies like in vitro fertilization (IVF) may be more likely to have preemies and kids with birth defects than their peers who conceive without difficulty, a U.S. study suggests.
Infertility has long been linked to an increased risk of premature deliveries, and the current study offered fresh evidence of this. Compared to women without any fertility issues, women who struggled to conceive were 39 percent more likely to have premature babies, while the increased risk associated with using reproductive technologies was 79 percent.
The study also found women who were “subfertile,” or struggled to conceive, were 21 percent more likely to have babies with birth defects than women who got pregnant without difficulty.
In addition, when researchers accounted for how early in pregnancy babies arrived, they found infants born to mothers with fertility issues or women who used ART were more likely to have congenital abnormalities, cardiovascular conditions, infectious diseases and respiratory problems.
“We think that medical conditions of the mother related to the subfertility are major drivers of adverse outcomes,” said senior study author Judy Stern of Dartmouth-Hitchcock in Lebanon, New Hampshire.
“It’s important to remember that the magnitude of any increase in risk is very small,” Stern said by email. “We are not talking about major differences in rates of disease conditions.”
Pregnancy normally lasts about 40 weeks, and babies born after 37 weeks are considered full term.
In the weeks immediately after birth, preemies often have difficulty breathing and digesting food. They can also encounter longer-term challenges such as impaired vision, hearing and cognitive skills, as well as social and behavioral problems.
For the study, researchers examined data on 336,705 infants born to fertile mothers in Massachusetts from 2004 to 2010, as well as 5,043 babies born to women with fertility problems and 8,375 infants whose mothers conceived using ART.
For some of the earliest preemies in the study, born from 28 to 33 weeks gestation, babies born using ART had a lower risk of birth defects than infants born to women with fertility problems who didn’t use ART, researchers report in Pediatrics.
Women’s fertility status or use of ART, however, didn’t appear to influence the risk that babies would be underweight, develop neurological or blood disorders, or die as newborns.
The study wasn’t a controlled experiment designed to prove whether or how fertility problems or ART might directly cause birth defects or certain diseases in babies. Another limitation is that researchers lacked data on some aspects of women’s health records and any fertility treatments that might impact the chance of babies having certain birth defects or health issues, the authors note.
Regardless of whether babies were born naturally or using ART, the vast majority were healthy, noted Logan Spector, a researcher at the University of Minnesota Medical School who wasn’t involved in the study.
“There has been a large a large amount of research showing that babies conceived by ART are smaller, have shorter gestations, and more birth defects than babies conceived naturally,” Spector said by email.
“However, a common drawback to these studies has been the difficulty of separating ART treatments from the underlying cause of infertility,” Spector added. “What this study adds is the finding that the health risks of infants born to subfertile mothers and those who had ART treatment are substantially similar, suggesting that subfertility is the common factor.”
SOURCE: bit.ly/2KHumqs Pediatrics, online July 3, 2018.

Tuesday, July 3, 2018

Projections for 5 Biggest Pharma Products in 2024


EvaluatePharma released its forward-looking report to 2024 that includes predictions of the best-selling prescription drugs.
The report, EvaluatePharma World Preview 2018, Outlook to 2024, said the total global pharmaceutical market in 2024 will have a value of $1.2 trillion. Orphan drugs are predicted to remain one of the fastest growth areas of the global pharmaceutical market, while the rare disease space is predicted to capture 20 percent of the total market in 2024, according to the report. With that being said though, the top five best-selling drugs in 2024 are quite familiar to the industry.
Writing in The Motley Fool, analyst Keith Speights lays out a quick review of the predicted best-sellers.
1.       Humira – AbbVie’s Humira is the top-selling drug in the world right now and that’s a spot it is likely to hold onto over the next six years, the report predicts. During the first quarter of 2018 sales of rheumatoid arthritis drug Humira grew 14.4 percent globally, including 11.4 percent growth in the United States. That growth means Humira generated $4.71 billion during the quarter. In 2017 it generates a total of $18.43 billion in revenue, about two-thirds of AbbVie’s revenue. Speights noted that Humira is likely to see a decline in earnings by 2024 to $15.2 billion as it faces increased competition from biosimilars and other products. But that competition isn’t expected to begin in the United States until 2023, so there’s plenty of time for AbbVie to earn billions.
2.       Keytruda – Merck will see significant gains from its strong cancer drug, Keytruda over the next six years. EvaluatePharma predicts the checkpoint inhibitor will bring in $12.7 billion in 2024 – up from the $3.8 billion it made in 2017. Part of the reason for the increase is the rapid pace in which Merck is seeking to gain regulatory approval for Keytruda in multiple indications, Speight said. The clinical successes of Keytruda continue to show why the checkpoint inhibitor is a key lynchpin in Merck’s pipeline. The drug is in late-stage trials for multiple types of cancer, including breast cancer, bladder cancer, renal cancer and small-cell lung cancer.
3.       Revlimid — Celgene’s blockbuster multiple myeloma drug Revlimid brought in about $8 billion in 2017, Speights said. EvaluatePharma believes that will increase to $11.9 billion in 2024. That prediction though could change as Revlimid continues to be challenged by other drugmakers. Speights noted that it’s likely Celgene, which is highly dependent on Revlimid revenue, will strike deals to hold off potential challengers.
4.       Opdivo – Bristol-Myers Squibb’s Opdivo, a key rival to Merck’s Keytruda, is projected to double its annual income by 2024. Last year the checkpoint inhibitor earned about $5.7 billion. In six years EvaluatePharma predicts annual revenue of $11.2 billion.
5.       Eliquis – Another BMS drug, Eliquis, a Factor Xa inhibitor used as an anticlotting treatment, is projected to bring home about $10.5 billion in 2024. While that is a nice annual return, Speights noted that BMS will share those earnings with Pfizer.
The EvaluatePharma predictions are just that, predictions. Any number of things could happen that alter the revenue projections. While Speights expressed some caution for investors using the predictions as a basis to buy stocks, he also predicted that the future will be especially bright for AbbVie, Celgene, and Pfizer.